Skip to content

Current ratio at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
6.2×+1.1×
ALN
Alnylam PharmaceuticalsALNY
3.1×+0.1×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
54.3×+48.3×
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
7.1×+0.3×
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
5.9×-0.1×

Other financials

Income statement

See full
Revenue$8.2M-12.8%
Operating income-$11.4M-14.4%
Net income-$9.1M-3.0%
EPS (diluted)-$0.54+53.8%

Balance sheet

See full
Cash & equivalents$31.1M+32.9%
Total debt$2.5M-17.5%
Total equity$198.6M+632%
Total assets$235.5M+138%

Cash flow

See full
Operating cash flow-$22.1M+5.7%
CapEx$19.0K
Free cash flow-$22.1M+5.6%

Valuation

See full
Market cap$480.77M+262%
Enterprise value$452.14M+302%
P/S6.8×+2.6×

Profitability

See full
Operating margin-116.8%-26.1pp
Net margin-103.6%-22.7pp
FCF margin-150%-231pp

Returns & leverage

See full
Return on equity-36.9%-15.1pp
Debt / equity-0.1×

Where this comes from

Calculated from Assembly Biosciences’s reported figures.

Based on the most recent quarter.

The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Assembly Biosciences's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Assembly Biosciences's current ratio?
Assembly Biosciences (ASMB) reported current ratio of 6.6× in Q1 2026.
How has Assembly Biosciences's current ratio changed year-over-year?
Assembly Biosciences's current ratio increased by 224.5% year-over-year, from 2× to 6.6×.
What is the long-term trend for Assembly Biosciences's current ratio?
Over 5 years (2020 to 2025), Assembly Biosciences's current ratio has grown at a -10.7% compound annual growth rate (CAGR), from 9.2× to 5.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.